In November 2016, Nearmedic presented the results of a unique post-registration study of the antiviral drug Kagocel in the framework of the international project «Treatment of SARS and influenza in routine clinical practice». The project was carried out jointly with the International Society of Internal Medicine in cooperation with the Eurasian Infectionists Society and the I. M. Sechenov First Moscow State Medical University. The data obtained in the study is unprecedented in scale. The project involved 262 medical centers from Russia, Moldova, Armenia and Georgia and over 18,000 patients aged 18 to 93 years with an established diagnosis of ARVI and influenza. The team of research physicians included primary care specialists, therapists, family doctors and general practitioners.
In the complex therapy of influenza and ARVI, Kagocel demonstrated effectiveness in patients of various ages and of different disease severity degrees, regardless of the time of prescription, including late treatment, against the background of a high level of safety. In the course of therapy with the drug, rapid relief of all the ARVI symptoms (chills, weakness, muscle and joint pains, rhinitis, sore throat, cough, scleritis or conjunctivitis, headache, fever) was noted. The use of Kagocel significantly reduces the number of complications with patients who received systemic antibacterial drugs by 51%.